Display options
Cite
Eby EL, Curtis BH, Gelwicks SC, et al. Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. BMJ Open Diabetes Res Care. 2015;3(1):e000074doi: 10.1136/bmjdrc-2014-000074.
Eby, E. L., Curtis, B. H., Gelwicks, S. C., Hood, R. C., Idris, I., Peters, A. L., Bergenstal, R. M., & Jackson, J. A. (2015). Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. BMJ open diabetes research & care, 3(1), e000074. https://doi.org/10.1136/bmjdrc-2014-000074
Eby, Elizabeth L, et al. "Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study." BMJ open diabetes research & care vol. 3,1 (2015): e000074. doi: https://doi.org/10.1136/bmjdrc-2014-000074
Eby EL, Curtis BH, Gelwicks SC, Hood RC, Idris I, Peters AL, Bergenstal RM, Jackson JA. Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. BMJ Open Diabetes Res Care. 2015 Apr 30;3(1):e000074. doi: 10.1136/bmjdrc-2014-000074. eCollection 2015. PMID: 25969741; PMCID: PMC4419461.
Copy Download .nbib Format: NLM
Share it on

BMJ Open Diabetes Res Care. 2015 Apr 30;3(1):e000074. doi: 10.1136/bmjdrc-2014-000074. eCollection 2015.

Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study.

BMJ open diabetes research & care

Elizabeth L Eby, Bradley H Curtis, Steven C Gelwicks, Robert C Hood, Iskandar Idris, Anne L Peters, Richard M Bergenstal, Jeffrey A Jackson

Affiliations

  1. Eli Lilly and Company , Indianapolis, Indiana , USA.
  2. Endocrine Clinic of Southeast Texas , Beaumont, Texas , USA.
  3. School of Graduate Entry Medicine, University of Nottingham , Nottingham , UK.
  4. Division of Endocrinology , Keck School of Medicine, University of Southern California , Los Angeles, California , USA.
  5. International Diabetes Center at Park Nicollet , Minneapolis, Minnesota , USA.
  6. Lilly USA, LLC , Indianapolis, Indiana , USA.

PMID: 25969741 PMCID: PMC4419461 DOI: 10.1136/bmjdrc-2014-000074

Abstract

AIM: Describe the characteristics of patients initiating human regular U-500 insulin (U-500R) and their subsequent glycemic control in a real-world setting.

METHODS: US Humedica electronic health record system data (July 2007-September 2011) were used to identify patients with diabetes aged ≥18 years with ≥1 records for U-500R prescriptions, 6 months of preindex data, 12 months following first use of U-500R, and at least one glycated hemoglobin (HbA1c) value in both preindex and postindex periods. Paired t tests were used to measure the change in HbA1c from preindex to postindex periods (last or most recent values) and hypoglycemia.

RESULTS: Among patients initiating U-500R (N=445), 96.9% had type 2 diabetes with mean age 57 years and mean body mass index 40.4 kg/m(2). Postindex prescriptions were written for U-500R alone (47.0%, group A) and concomitant U-500R/U-100 insulins (53.0%, group B). Concomitant oral antihyperglycemic agents (AHAs) and non-insulin injectable AHAs were used by 43.4% and 14.6% of patients, respectively. Following initiation of U-500R, mean HbA1c improved 0.68% in all patients (p<0.0001 compared with baseline), but the decrease in HbA1c did not differ significantly between groups (A: 0.78%; B: 0.60%). Overall, hypoglycemic events, largely captured in the outpatient setting, increased in incidence from 6.7% to 11.9% (p≤0.0001) and from 0.23 to 0.39 events/patient/year, an increase of 0.16 (p=0.003), from preindex to postindex.

CONCLUSIONS: This real-world outcomes analysis demonstrates that U-500R initiation is associated with a clinically meaningful improvement in glycemic control over the subsequent 12-month period with modest increase in incidence and rate of hypoglycemia.

Keywords: Glycemic Control; Hypoglycemia; Insulin Resistance; Management

References

  1. Diabetes Care. 2015 Jan;38(1):140-9 - PubMed
  2. Diabetes Technol Ther. 2013 Apr;15(4):342-3 - PubMed
  3. Endocr Pract. 2014 Jul;20(7):663-70 - PubMed
  4. Diabetes Care. 2012 Jun;35(6):1364-79 - PubMed
  5. Obstet Gynecol. 2013 Jul;122(1):99-104 - PubMed
  6. Diabetes Care. 2010 Feb;33(2):281-3 - PubMed
  7. BMC Endocr Disord. 2008 Apr 01;8:4 - PubMed
  8. J Med Econ. 2013;16(4):529-38 - PubMed
  9. Diabetes Care. 2013 May;36(5):1384-95 - PubMed
  10. J Diabetes Sci Technol. 2012 Mar 01;6(2):412-20 - PubMed
  11. Diabetes Obes Metab. 2013 Oct;15(10):882-7 - PubMed
  12. Diabetes Technol Ther. 2012 Jun;14(6):505-7 - PubMed
  13. Endocr Pract. 2012 Jan-Feb;18(1):34-8 - PubMed
  14. Diabetes Educ. 2014 Mar-Apr;40(2):153-65 - PubMed
  15. Diabetes Care. 2005 May;28(5):1240-4 - PubMed
  16. Endocr Pract. 2010 Sep-Oct;16(5):778-84 - PubMed
  17. J Diabetes Sci Technol. 2014 Jul;8(4):821-9 - PubMed
  18. Endocr Pract. 2013 Mar-Apr;19(2):196-201 - PubMed
  19. Diabetes Metab Res Rev. 2007 May;23(4):265-8 - PubMed
  20. Endocr Pract. 2012 Jan-Feb;18(1):56-61 - PubMed
  21. Am J Health Syst Pharm. 2010 Sep 15;67(18):1526-35 - PubMed
  22. Diabetes Obes Metab. 2013 Jun;15(6):485-502 - PubMed
  23. Diabetes Res Clin Pract. 2010 Dec;90(3):231-42 - PubMed
  24. Endocr Pract. 2014 Nov;20(11):1143-50 - PubMed
  25. Diabetes Care. 2011 Dec;34(12):2496-501 - PubMed
  26. Diabetes Technol Ther. 2011 May;13(5):592-5 - PubMed
  27. Endocr Pract. 2013 May-Jun;19(3):536-57 - PubMed
  28. Endocr Pract. 2009 Jan-Feb;15(1):71-9 - PubMed
  29. Diabetes Res Clin Pract. 2012 Mar;95(3):340-4 - PubMed

Publication Types